Anacetrapib vs Placebo Anacetrapib: Number of Participants With Major Coronary Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.108 | 0.103 | 0.113 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.118 | 0.113 | 0.124 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0107 | -0.0178 | -0.0036 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.91 | 0.854 | 0.969 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.899 | 0.837 | 0.965 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Anacetrapib than on Placebo Anacetrapib | 93.3 | 56.1 | 278 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Anacetrapib | Anacetrapib: 100mg tablet daily | 1,640 | 15,225 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo Anacetrapib | Placebo anacetrapib: 1 tablet daily | 1,803 | 15,224 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Major Coronary Event | ClinicalTrials.gov |
| Description | Primary assessment involves an intention-to-treat comparison among all randomized participants of the effects of allocation to anacetrapib versus placebo on major coronary events (defined as the occurrence of coronary death, myocardial infarction or coronary revascularization procedure) during the scheduled treatment period.~Data reported is for the first major coronary event. | ClinicalTrials.gov |
| Time frame | Randomized treatment phase during median follow-up period of 4.1years | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | ClinicalTrials.gov |
| NCT number | NCT01252953 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Atherosclerotic Cardiovascular Disease | ClinicalTrials.gov |
| Interventions | Anacetrapib, Placebo anacetrapib | ClinicalTrials.gov |
| Lead sponsor | University of Oxford | ClinicalTrials.gov |
| Results first posted | 2018-05-04 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01252953?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.